{"filing":{"accession_number":"0001213900-26-086939","cik":"0001821586","ticker":"MLTX","company_name":"MoonLake Immunotherapeutics","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"ea0301191-8k_moonlake.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/ea0301191-8k_moonlake.htm"},"events":[{"id":26352,"run_id":23943,"accession_number":"0001213900-26-086939","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"MoonLake disclosed second quarter 2026 financial results via press release dated August 10, 2026, reporting cash position of $537.0 million, R\u0026D expenses of $50.2 million, G\u0026A expenses of $11.4 million, and cash runway to mid-2028. The press release also announced positive topline Week 16 results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, meeting all clinical endpoints.","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27443,"accession_number":"0001213900-26-086939","item_number":"2.02","item_title":"Results of Operations and","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses MoonLake's second quarter 2026 financial results via a press release dated August 10, 2026, including cash position ($537.0 million), R\u0026D expenses ($50.2 million), and G\u0026A expenses ($11.4 million). While the press release also announces positive Phase 3 IZAR-1 trial results for sonelokimab in psoriatic arthritis, the Item 2.02 disclosure is explicitly framed as reporting \"financial results for the quarter ended June 30, 2026,\" making this a classic earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:16:59.342362+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27444,"accession_number":"0001213900-26-086939","item_number":"7.01","item_title":"Regulation FD","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses positive topline Week 16 results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, meeting all clinical endpoints, along with second quarter 2026 financial results including cash position ($537.0 million) and cash runway to mid-2028. While the primary disclosure is clinical trial results rather than traditional earnings, the press release explicitly reports \"Second Quarter 2026 Financial Results\" and includes material financial metrics (cash, R\u0026D expenses, G\u0026A expenses), making this a hybrid clinical-and-financial disclosure. The clinical trial success is material to investors assessing the company's pipeline and value, and the financial results are explicitly reported in the same press release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:16:59.342362+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27443,"accession_number":"0001213900-26-086939","item_number":"2.02","item_title":"Results of Operations and","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses MoonLake's second quarter 2026 financial results via a press release dated August 10, 2026, including cash position ($537.0 million), R\u0026D expenses ($50.2 million), and G\u0026A expenses ($11.4 million). While the press release also announces positive Phase 3 IZAR-1 trial results for sonelokimab in psoriatic arthritis, the Item 2.02 disclosure is explicitly framed as reporting \"financial results for the quarter ended June 30, 2026,\" making this a classic earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:16:59.342362+00:00","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-08-10"},{"id":27444,"accession_number":"0001213900-26-086939","item_number":"7.01","item_title":"Regulation FD","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses positive topline Week 16 results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, meeting all clinical endpoints, along with second quarter 2026 financial results including cash position ($537.0 million) and cash runway to mid-2028. While the primary disclosure is clinical trial results rather than traditional earnings, the press release explicitly reports \"Second Quarter 2026 Financial Results\" and includes material financial metrics (cash, R\u0026D expenses, G\u0026A expenses), making this a hybrid clinical-and-financial disclosure. The clinical trial success is material to investors assessing the company's pipeline and value, and the financial results are explicitly reported in the same press release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:16:59.342362+00:00","company_name":"MoonLake Immunotherapeutics","ticker":"MLTX","filing_date":"2026-08-10"}]}